Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504123 | 0.92 | MAPT (0.47) | MEN1KMT2AMAPTTSHRGRIN2B | |
| SCHEMBL17504185 | 0.89 | MAPT (0.45) | MEN1KMT2AMAPTTSHRGRIN2B | |
| SCHEMBL17504125 | 0.85 | MEN1 (0.59) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL17504156 | 0.80 | GRIN2B (0.46) | MEN1KMT2AMAPTTSHRGRIN2B | |
| SCHEMBL17504167 | 0.78 | MEN1 (0.68) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL17504136 | 0.76 | KDM4E (0.41) | MEN1KMT2AMAPTKDM4EGPBAR1 | |
| SCHEMBL17504153 | 0.74 | KDM4E (0.46) | MEN1KMT2AKDM4EGPBAR1TSPO | |
| SCHEMBL17504144 | 0.70 | TSPO (0.40) | MEN1KMT2AMAPTGRIN2BALDH1A1 | |
| SCHEMBL23297365 | 0.65 | HDAC1 (0.60) | MEN1KMT2AMAPTTSHRSMN1; SMN2 | |
| SCHEMBL17504176 | 0.64 | MEN1 (0.48) | MEN1KMT2AMAPTTSHRGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180319-B1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP3A43, CYP4B1 | MEN1 3241/4885KMT2A 2716/4885MAPT 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.